Fig. 6
From: Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform
Immunogenicity and protective efficacy in mice of engineered-EVs. Antibody levels in sera (diluted 1:100) from mice immunized with eng-EVs were analyzed on ELISA plates coated with a JE2 sonicated EVs, b Hla, or c LukE. Data were expressed as mean ± s.e.m. The neutralizing activity of sera from mice immunized with BSA or different EV preparations was determined by either incubating serial dilutions of sera with d Hla, e LukED, or f, or HlgAB for 1 h at 37 °C before adding target cells. Control cells were incubated with toxins but no sera. Data are expressed as percent neutralization ± s.e.m. Mice (n = 8) immunized with different JE2 EV preparations were challenged IV with 8 × 107 CFU S. aureus LAC (g) or 2 × 108 NRS685 (h). Survival (comparing EV-immunized mice vs. BSA-immunized mice) was analyzed with the log-rank test
